Evidence map›Paper›PMID 31035079›Full record

Observational studyAddictive behaviors2019

Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs.

Risha Irvin, Geetanjali Chander, Oluwaseun Falade-Nwulia, Jacquie Astemborski, Laura Starbird, Gregory D Kirk, Mark S Sulkowski, David L Thomas, Shruti H Mehta

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Addictive behaviors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Risha IrvinDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: rirvin1@jhmi.edu.
Geetanjali ChanderDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Oluwaseun Falade-NwuliaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Jacquie AstemborskiDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Laura StarbirdJohns Hopkins School of Nursing, Baltimore, MD, United States.
Gregory D KirkDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Mark S SulkowskiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
David L ThomasDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Johns Hopkins University · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
INCIDENCE OF HIV INFECTIONS IN A COHORT OF IV DRUG USERSR01DA012568 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MEHTA, SHRUTI H · 1999 to 2017
$15.5M
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV EliminationR01DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI IRVIN, RISHA, THOMAS, DAVID L · 2000 to 2024
$8.7M
Management/Hepatitis C/HIV-infected and Uninfected IDU'sR01DA016065 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2003 to 2018
$8.0M
HIV HCV Coinfection Antiviral Therapy and FibrosisR37DA013806 · NIDA · JOHNS HOPKINS UNIVERSITY · PI THOMAS, DAVID L · 2010 to 2019
$7.0M
Systems Science and Comparative and Cost-Effectiveness Research Training for Nurse Scientists (S2CER2)T32NR014205 · NINR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Lusine Poghosyan, Jingjing Shang · 2013 to 2026
$4.2M
Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugsR01DA048063 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta, David L Thomas · 2019 to 2026
$4.2M
1/4 Alcohol Research Consortium in HIV-Administrative Core (ARCH-AC)U24AA020801 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI CHANDER, GEETANJALI, MCCAUL, MARY E · 2011 to 2021
$3.5M
Mentoring and Patient Oriented Research at the Nexus of Unhealthy Alcohol Use and HIVK24AA027483 · NIAAA · UNIVERSITY OF WASHINGTON · PI GEETANJALI CHANDER · 2019 to 2026
$1.3M
Patient Oriented Research in Hepatitis C-infected Injection Drug UsersK24DA034621 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SULKOWSKI, MARK SEBASTIAN · 2012 to 2022
$1.2M
The impact of social networks on hepatitis C transmission and care access in people who inject drugsK23DA041294 · NIDA · JOHNS HOPKINS UNIVERSITY · PI FALADE-NWULIA, OLUWASEUN · 2016 to 2020
$924k
NIAAA NIH HHS K24 AA027483NIAAA NIH HHS U24 AA020801NIAID NIH HHS K24 AI118591NIAID NIH HHS P30 AI094189NIDA NIH HHS K23 DA041294NIDA NIH HHS K24 DA034621NIDA NIH HHS R01 DA012568NIDA NIH HHS R01 DA013806NIDA NIH HHS R01 DA016065NIDA NIH HHS R01 DA048063NIDA NIH HHS R37 DA013806NIDA NIH HHS U01 DA036297NINR NIH HHS F31 NR016200NINR NIH HHS L30 NR018771NINR NIH HHS T32 NR014205
6 · The paper itself

Abstract

backgroundAlcohol use in people who inject drugs (PWID) with hepatitis C virus (HCV) infection accelerates liver disease progression. This paper describes the prevalence and associated correlates of alcohol use among HCV antibody positive PWID.

methodsIn a large cohort of HCV antibody positive PWID (N = 1623) followed from 2005 to 2013, we characterized alcohol use using the AUDIT-C. We used multivariable logistic regression with generalized estimated equations to examine socio-demographic, clinical, and substance use correlates of alcohol use.

resultsAt their initial visit, 41% reported no, 21% reported moderate, and 38% reported heavy alcohol use. The odds of moderate and heavy alcohol use increased with greater intensity of substance use represented by a composite summary variable which ranged from 0 to 3 substances (street-acquired prescription drugs, non-injection cocaine/heroin, and injection drugs) used. Compared to those who used no drugs, those who used 3 substances had 3.71 odds (95% CI: 3.07-4.48) of moderate alcohol use and 3.65 odds (95% CI: 3.20-4.16) of heavy alcohol use.

conclusionsThe prevalence of moderate/heavy alcohol use is high among HCV antibody positive PWID and occurs frequently in combination with other drug use. This may contribute to progressive liver fibrosis thus limiting the gains achieved from HCV cure. Public health interventions need to address the overlapping epidemics of HCV, alcohol use, and other substance use in this population.

Indexed as

AdultAlcohol DrinkingAlcoholismCocaine-Related DisordersEpidemicsFemaleHepatitis C, ChronicHeroin DependenceHIV InfectionsHumansMaleMiddle AgedPrevalenceSubstance Abuse, IntravenousAlcohol useHepatitis C virusInjection drug useSubstance use

Identifiers

PMID31035079
PMCPMC6718047
OpenAlexW2940727295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.